Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.66 |
| ▸ | BPTF | Q12830 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NQO1 | P15559 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23732273 | 1.00 | CHRNB2 (0.66) | CHRNB2CHRNA4BPTFMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL23199740 | 0.98 | CHRNB2 (0.68) | CHRNB2CHRNA4BPTFMAPTNPC1 | |
| SCHEMBL23732367 | 0.81 | BPTF (0.59) | CHRNB2CHRNA4BPTFSMN1; SMN2LMNA | |
| SCHEMBL20510328 | 0.81 | BPTF (0.59) | CHRNB2CHRNA4BPTFSMN1; SMN2LMNA | |
| SCHEMBL649885 | 0.81 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL649887 | 0.81 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL650002 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL650001 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL21667797 | 0.79 | BPTF (0.61) | CHRNB2CHRNA4BPTFMAPTNPC1 | |
| SCHEMBL23744796 | 0.79 | MAPT (0.53) | CHRNB2CHRNA4MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365984-B | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2024-10-15 | — | — | CN | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3880664-A1 | LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-09-22 | — | — | EP | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802541-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | CHRNB2 3882/4885CHRNA4 4539/4885BPTF 3130/4885 |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | CHRNB2 1327/4885CHRNA4 1249/4885BPTF 4706/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | CHRNB2 1327/4885CHRNA4 1249/4885BPTF 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.